Related Experiment Video
Updated: Oct 17, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
AMBRA1 and FAK1: crosstalking for improved targeted therapy in melanoma
1Melanoma Research Team, Cell Stress and Survival Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
Abstract:
Through genetically engineered mouse models of melanoma, we identified Autophagy/beclin 1 regulator 1 (Ambra1) as novel tumor-suppressor in melanoma. In these settings, loss of Ambra1 associated with the hyperactivation of focal adhesion kinase 1 (Fak1) signaling, the inhibition of which resulted in reduced tumor growth and invasiveness. We therefore propose FAK1 inhibition for current melanoma therapy in AMBRA1-low tumors.
Abbreviations:
AKT, serine/threonine kinase 1; AMBRA1, autophagy/beclin 1 regulator 1; BRAF, v-raf murine sarcoma viral oncogene homolog; BRAFi, BRAF inhibitor; CCLE, Cancer Cell Line Encyclopedia;g ESTDAB, European Searchable Tumor Line Database; FAK1, focal adhesion kinase 1; FAKi, FAK1 inhibitor; LMC, Leeds Melanoma Cohort; MEK, MAPK/ERK kinase; PP2A, protein phosphatase 2A; PTEN, phosphatase and tensin homolog; TCGA-SKCM, The Cancer Genome Atlas - Skin Cutaneous Melanoma; YAP, yes-associated protein 1.
Insights
Autophagy/beclin 1 regulator 1 (Ambra1) acts as a tumor suppressor in melanoma. Inhibiting focal adhesion kinase 1 (Fak1) reduces tumor growth, suggesting FAK1 inhibitors for AMBRA1-low melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Melanoma is a significant skin cancer with complex molecular underpinnings.
- Understanding novel tumor suppressors and signaling pathways is crucial for developing effective therapies.
- Autophagy/beclin 1 regulator 1 (Ambra1) and focal adhesion kinase 1 (Fak1) signaling are implicated in cancer progression.
Purpose of the Study:
- To identify novel tumor suppressors in melanoma.
- To investigate the role of Ambra1 in melanoma development and progression.
- To explore the therapeutic potential of targeting Fak1 signaling in Ambra1-low melanoma.
Main Methods:
- Utilized genetically engineered mouse models of melanoma.
- Assessed the association between Ambra1 expression and Fak1 signaling.
- Evaluated the effect of Fak1 inhibition on tumor growth and invasiveness.
Main Results:
- Identified Ambra1 as a novel tumor suppressor in melanoma.
- Demonstrated that loss of Ambra1 correlates with hyperactivation of Fak1 signaling.
- Showed that Fak1 inhibition significantly reduces melanoma tumor growth and invasiveness.
Conclusions:
- Ambra1 functions as a tumor suppressor in melanoma.
- Targeting Fak1 signaling represents a promising therapeutic strategy for AMBRA1-low melanoma.
- FAK1 inhibition warrants further investigation for melanoma treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...